DP-R213 Phase 1 Pharmacokinetics Study

NCT03010267 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: DP-R213
DRUG: Raloxifene
DRUG: Cholecaliferol

Sponsor

Alvogen Korea